Opinion

Managing third-party risks in the life sciences industry

January 27, 2015

Internal compliance reviews are not enough; life sciences companies need to assess their third-party business partners

The Price of Global Health

January 27, 2015

Defining 'market access'

A brightening outlook for pharma

November 03, 2014

The Impending AMP Rule, still waiting three years later

October 30, 2014

Some state-level changes give an indication of what to prepare for

Economic and clinical value: the future of cancer care

October 30, 2014

An 'expectations convergence' is building in how drug efficacy aligns with patient outcomes

Legal uncertainties in the DSCSA

August 29, 2014

The Drug Supply Chain Security Act creates uncertainty about which trading partners have responsibility for product verification

Is tech running you? Four ways to retake control

August 29, 2014

Modern training technologies make the prospect of days-long training courses an obsolete practice

Converging the pharma business with its logistics and data functions

August 29, 2014

Pharma in China--calculated risk gone wrong

June 26, 2014

Doing business in China is undergoing important changes

Industry should reinforce cargo security practices with TAPA participation

June 26, 2014

Ultimately, supply chain integrity should include both temperature control and security against theft or diversion